TGFB1 and neoplasm: High levels of transforming growth factor-beta (TGF-β) signaling in these tumors further promote an immunosuppressive environment, often confining immune cells to the periphery of the tumor and reducing the efficacy of immune checkpoint inhibitors (73–85).